Macro Momentum ETF Jumps 0.71% on Medtronic FDA Clearance for Spine Tech
Strategas Macro Momentum ETF shares climbed 0.71% after Medtronic secured FDA clearance for its Stealth AXiS spine surgery system featuring LiveAlign segmental tracking to cut repeat imaging. The integrated planning and navigation platform’s hospital and ambulatory surgery center applications could boost medtech-focused ETF constituents.
1. Share Price Reaction
Shares of Strategas Macro Momentum ETF rose 0.71% following the FDA’s clearance of Medtronic’s Stealth AXiS system, reflecting investor optimism toward advanced medtech innovations within the ETF’s portfolio.
2. Medtronic Stealth AXiS Approval
The FDA granted clearance for Stealth AXiS spine surgery system, which integrates real-time LiveAlign segmental tracking to reduce repeat imaging and streamline surgical workflows across hospitals and ambulatory centers.
3. Potential ETF Impact
Medtronic is a key holding in the ETF’s biomedical device segment; approval of its integrated navigation platform may enhance sentiment and performance of other device and technology stocks within the fund.